Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 17/20 | 0.71 |
| ▸ | LCK | P06239 | 10/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | EGFR | P00533 | 2/20 | 0.55 |
| ▸ | SRC | P12931 | 2/20 | 0.55 |
| ▸ | KDR | P35968 | 2/20 | 0.55 |
| ▸ | ZAP70 | P43403 | 2/20 | 0.55 |
| ▸ | JAK3 | P52333 | 2/20 | 0.55 |
| ▸ | JAK2 | O60674 | 1/20 | 0.55 |
| ▸ | RAD52 | P43351 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2976792 | 0.83 | TNK2 (1.00) | TNK2LCKKMT2AMEN1EGFR | |
| SCHEMBL2965891 | 0.82 | TNK2 (1.00) | TNK2LCK | |
| SCHEMBL2962544 | 0.82 | TNK2 (0.85) | TNK2LCKKMT2AMEN1EGFR | |
| SCHEMBL2961061 | 0.82 | TNK2 (1.00) | TNK2LCKKMT2AMEN1EGFR | |
| SCHEMBL2965913 | 0.81 | TNK2 (1.00) | TNK2LCKKMT2AMEN1EGFR | |
| SCHEMBL5312643 | 0.80 | TNK2 (0.71) | TNK2LCKKMT2AMEN1EGFR | |
| SCHEMBL2970642 | 0.79 | TNK2 (0.92) | TNK2LCKKMT2AMEN1EGFR | |
| SCHEMBL2970697 | 0.79 | TNK2 (0.73) | TNK2LCKKMT2AMEN1EGFR | |
| SCHEMBL3572027 | 0.78 | TNK2 (0.60) | TNK2LCKKMT2AMEN1KDR | |
| SCHEMBL2966416 | 0.78 | TNK2 (0.82) | TNK2LCKKMT2AMEN1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776867-B2 | Furanopyrimidines | AMGEN INC. (US) | 2010-08-17 | — | — | US | claimed |
| US-20060040961-A1 | Furanopyrimidines | AMGEN INC. | 2006-02-23 | — | — | US | claimed |
| US-7776867-B2 | Furanopyrimidines | AMGEN INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-7776867-B2 | Furanopyrimidines | AMGEN INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-7776867-B2 | Furanopyrimidines | AMGEN INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20060040961-A1 | Furanopyrimidines | AMGEN INC. | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040961-A1 | Furanopyrimidines | TYMS, IDO1, NFATC1 | TNK2 1075/4885LCK 18/4885KMT2A 4672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.